Compare CTGO & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTGO | PRME |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.7M | 526.0M |
| IPO Year | 2010 | 2022 |
| Metric | CTGO | PRME |
|---|---|---|
| Price | $16.87 | $3.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $31.17 | $7.11 |
| AVG Volume (30 Days) | 349.7K | ★ 3.0M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.77 | 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | $90.67 |
| Revenue Next Year | N/A | $19.46 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $14.50 | $2.67 |
| 52 Week High | $34.38 | $6.85 |
| Indicator | CTGO | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 44.33 |
| Support Level | $14.99 | $2.77 |
| Resistance Level | $17.92 | $3.70 |
| Average True Range (ATR) | 0.88 | 0.23 |
| MACD | -0.28 | -0.02 |
| Stochastic Oscillator | 10.77 | 31.45 |
Contango Silver & Gold Inc, formerly Contango Ore Inc operates in the United States. The company is engaged in the exploration for and development of gold ore and associated minerals in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin, whose governmental entity is the Tetlin Tribal Council, for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.